Krystal Biotech (KRYS) to Release Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) will be posting its quarterly earnings results before the market opens on Monday, November 4th. Analysts expect Krystal Biotech to post earnings of $0.84 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period last year, the company earned ($1.25) earnings per share. Krystal Biotech’s quarterly revenue was up 70283900.0% on a year-over-year basis. On average, analysts expect Krystal Biotech to post $3 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Krystal Biotech Stock Up 2.2 %

NASDAQ:KRYS opened at $176.39 on Friday. The company has a market cap of $5.07 billion, a P/E ratio of 48.33 and a beta of 0.82. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $219.34. The business has a 50 day moving average price of $182.88 and a two-hundred day moving average price of $179.93.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Analysts Set New Price Targets

KRYS has been the subject of a number of analyst reports. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Citigroup reissued a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. HC Wainwright increased their price objective on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).